Trial Profile
A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Tasadenoturev (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 17 Feb 2022 Results published in the Clinical Cancer Research
- 22 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01582516).
- 22 Apr 2012 Additional lead trial centres and investigator identified as reported by ClinicalTrials.gov.